ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
PedAL BCU, LLC
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
AstraZeneca
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Sanofi
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Stanford University
Thomas Jefferson University
M.D. Anderson Cancer Center
Instituto Nacional de Cancer, Brazil
Astex Pharmaceuticals, Inc.
Columbia University
Indiana University
Shenzhen TargetRx Co., Ltd.
University Hospital, Basel, Switzerland
Indiana University
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
University of Nebraska
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
GT Biopharma, Inc.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Chinese PLA General Hospital
Incyte Corporation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Gamida Cell ltd
M.D. Anderson Cancer Center
Novartis
Gamida Cell ltd
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
M.D. Anderson Cancer Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Milton S. Hershey Medical Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota